Lincoln Capital Corp Acquires 247 Shares of Cencora, Inc. (NYSE:COR)

Lincoln Capital Corp raised its holdings in Cencora, Inc. (NYSE:COR) by 1.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,258 shares of the company’s stock after acquiring an additional 247 shares during the quarter. Cencora comprises 2.1% of Lincoln Capital Corp’s portfolio, making the stock its 16th largest position. Lincoln Capital Corp’s holdings in Cencora were worth $5,235,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. New Millennium Group LLC acquired a new position in shares of Cencora during the 2nd quarter worth about $26,000. TCTC Holdings LLC bought a new position in Cencora during the 1st quarter worth approximately $29,000. TFO Wealth Partners LLC acquired a new position in Cencora during the first quarter valued at approximately $30,000. MFA Wealth Advisors LLC bought a new stake in Cencora in the second quarter valued at approximately $30,000. Finally, LRI Investments LLC acquired a new stake in Cencora in the first quarter worth $31,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on COR shares. Robert W. Baird decreased their price target on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a report on Friday, September 6th. Wells Fargo & Company raised their price target on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Bank of America reiterated a “neutral” rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Finally, Leerink Partners cut their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $259.44.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,461,153 shares of company stock worth $1,073,075,720. Insiders own 15.80% of the company’s stock.

Cencora Trading Down 0.3 %

Shares of NYSE:COR opened at $234.47 on Friday. The company’s 50-day moving average price is $232.15 and its two-hundred day moving average price is $230.87. Cencora, Inc. has a one year low of $182.75 and a one year high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The stock has a market capitalization of $46.77 billion, a PE ratio of 25.65, a price-to-earnings-growth ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR) last released its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.18 by $0.16. The business had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. Cencora’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.92 earnings per share. On average, equities analysts forecast that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were paid a $0.51 dividend. The ex-dividend date was Friday, August 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.87%. Cencora’s dividend payout ratio is presently 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.